Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

Journal Articles

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

Carla Maria Boquimpani, MD, Tomasz Szczudlo, MD, Estella Mendelson, BSRN, MBA, Katy Benjamin, PhD, Tamás Masszi, MD PhD

Blood (2014) 124 (21): 4547.

https://doi.org/10.1182/blood.V124.21.4547.4547

Published: 2014

Journal Articles

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Timothy P. Hughes, Jeffrey H. Lipton, Nelson Spector, Francisco Cervantes, Ricardo Pasquini, Nelma Cristina D. Clementino, Pedro Enrique Dorlhiac Llacer, Anthony P. Schwarer, Francois-Xavier Mahon, Delphine Rea, Susan Branford, Das Purkayastha, LaTonya Collins, Tomasz Szczudlo, Brian Leber

Blood (2014) 124 (5): 729–736.

https://doi.org/10.1182/blood-2013-12-544015

Published: 2014

Journal Articles

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Jorge E. Cortes, MD, Carmino Antonio De Souza, PhD, Jose Luis Lopez, MD, Manuel Ayala, MD, Eduardo Bullorsky, Xiaojun Huang, Sandip Shah, K. Govind Babu, Tomasz Sacha, MD, Israel Bendit, Zhizhou Liang, Tina Owugah, Prasanna Kumar Nidamarthy, Tomasz Szczudlo, Carmen Piccolo, MD, Philipp D. le Coutre, MD

Blood (2013) 122 (21): 95.

https://doi.org/10.1182/blood.V122.21.95.95

Published: 2013

Journal Articles

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Brian Leber, MD, Francisco Cervantes, MD, PhD, Nelson Spector, MD, PhD, Jeffrey H. Lipton, MD, PhD, Gabriel Etienne, MD, PHD, Ricardo Pasquini, MD, PhD, Nelma Christina Clementino, MD, Agnès Guerci-Bresler, MD, Donna Forrest, MD, FRCPC, Anthony P. Schwarer, MD, Sandip Acharya, LaTonya Collins, BSN, Tomasz Szczudlo, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 94–95.

https://doi.org/10.1182/blood.V122.21.94.94

Published: 2013

Journal Articles

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD, PhD, Sang Kyun Sohn, MD, PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD, PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 1499.

https://doi.org/10.1182/blood.V122.21.1499.1499

Published: 2013

Journal Articles

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Nelson Spector, MD, PhD, Brian Leber, MD, Ricardo Pasquini, MD, PhD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Gabriel Etienne, MD, PhD, Agnès Guerci-Bresler, MD, Susan Branford, PhD, Das Purkayastha, LaTonya Collins, BSN, Tomasz Szczudlo, Francisco Cervantes, MD, PhD

Blood (2012) 120 (21): 694.

https://doi.org/10.1182/blood.V120.21.694.694

Published: 2012

Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Blood (2012) 120 (21): 3775.

https://doi.org/10.1182/blood.V120.21.3775.3775

Published: 2012

Journal Articles

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Brian Leber, MD, Nelson Spector, MD, PhD, Francisco Cervantes, MD, PhD, Ricardo Pasquini, MD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Suzanne Kamel-Reid, PhD, Israel Bendit, MD, John Reynolds, PhD, Lisa Williams, Tomasz Szczudlo, Susan Branford, PhD

Blood (2011) 118 (21): 606.

https://doi.org/10.1182/blood.V118.21.606.606

Published: 2011

Journal Articles

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Hyun-Gyung Goh, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk-Joong Oh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Sung-Eun Lee, Dongho Kim, Ji-Young Byeun, Richard C. Woodman, Tomasz Szczudlo, Hee Jung Kim, Dong-Wook Kim

Blood (2011) 118 (21): 2765.

https://doi.org/10.1182/blood.V118.21.2765.2765

Published: 2011

Journal Articles

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

Jennifer L Beaumont, MS, Cindy Nowinski, MD PhD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Rick E. Blakesley, PhD, Neil J. Gallagher, MD, PhD, James Burns, MS, David Cella, PhD

Blood (2011) 118 (21): 1025.

https://doi.org/10.1182/blood.V118.21.1025.1025

Published: 2011

Journal Articles

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

François Guilhot, MD, John Coombs, PharmD, MBA, Tomasz Szczudlo, Oleg Zernovak, MD, Nancy J. Macdonald, PhD, Ari Shapiro, PhD

Blood (2010) 116 (21): 394.

https://doi.org/10.1182/blood.V116.21.394.394

Published: 2010

Journal Articles

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

François Guilhot, MD, John Coombs, PharmD, MBA, Oleg Zernovak, MD, Tomasz Szczudlo, Gianantonio Rosti

Blood (2010) 116 (21): 1514.

https://doi.org/10.1182/blood.V116.21.1514.1514

Published: 2010

Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 2201.

https://doi.org/10.1182/blood.V114.22.2201.2201

Published: 2009

Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Blood (2009) 114 (22): 3293.

https://doi.org/10.1182/blood.V114.22.3293.3293

Published: 2009

Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 3286.

https://doi.org/10.1182/blood.V114.22.3286.3286

Published: 2009

Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 1115.

https://doi.org/10.1182/blood.V114.22.1115.1115

Published: 2009

Journal Articles

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Jeffrey H. Lipton, MD, PhD, Philipp D. le Coutre, MD, Jim Wang, PhD, Mindy Yang, PharmD, Tomasz Szczudlo, MD, Francis Giles, MD

Blood (2008) 112 (11): 3233.

https://doi.org/10.1182/blood.V112.11.3233.3233

Published: 2008

Journal Articles

Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program

Alan S. Wayne, MD, Carla Renata Macedo, MD, Tomasz Szczudlo, MD, Richard C. Woodman, MD

Blood (2008) 112 (11): 4264.

https://doi.org/10.1182/blood.V112.11.4264.4264

Published: 2008

Journal Articles

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Philipp D. le Coutre, MD, Michael O’Dwyer, MD, FRCPI, FRCPath, Tomasz Szczudlo, MD, Richard C. Woodman, MD, Francis J. Giles, MD

Blood (2008) 112 (11): 4271.

https://doi.org/10.1182/blood.V112.11.4271.4271

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Attitudes and Perceptions of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Toward Treatment-Free Remission (TFR)

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?

An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies

A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program

Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only